Meningococcal Serogroup B Vaccines Can Be Approved With Surrogate Endpoints, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Traditional placebo-controlled trials would require an impractically large patient population, the agency says as it seeks advisory committee input on post-marketing requirements.
You may also be interested in...
Pfizer, Novartis Get Advisory Panel Backing For General Methods Of Meningococcal Vaccine Trials
Pfizer appears to be slightly ahead of Novartis in planning a Phase III clinical trial of a vaccine against meningococcal serogroup B, with an anticipated start date later this year.
Pfizer, Novartis Get Advisory Panel Backing For General Methods Of Meningococcal Vaccine Trials
Pfizer appears to be slightly ahead of Novartis in planning a Phase III clinical trial of a vaccine against meningococcal serogroup B, with an anticipated start date later this year.
Pediatric Meningococcal Vaccine's Approval Pathway May Work For Other Disease Areas
FDA suggests serum bactericidal antibody measurements to predict protection from meningococcal diseases in children under age 2.